Association of ocular adverse events with varenicline solution use: a population-based study

Expert Opinion on Drug Safety, Год журнала: 2025, Номер unknown, С. 1 - 9

Опубликована: Фев. 8, 2025

Background Approved by the FDA in 2021, varenicline solution is first nasal spray specifically designed to enhance basal tear film production for treating dry eye disease (DED). However, there a lack of data comprehensively comparing its safety profile conventional DED therapies. Herein, we assess whether ocular adverse events (AEs) are disproportionately reported with real-world use solution.

Язык: Английский

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study

Ophthalmology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Фев. 22, 2025

Perfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms dry eye disease (DED) targets excessive tear evaporation. This study evaluated patient-reported outcomes early in with PFHO. prospective, multicenter, open-label, phase 4 enrolled adults a history DED ≥ 6 months. PFHO was instilled both eyes four times daily 14 days. Patients completed outcome surveys during clinic visits (day 1 [pretreatment; 5 60 min post-PFHO instillation] days 3, 7, 14). Symptom severity, symptom frequency, satisfaction were rated on visual analog scales (range 0–100). The primary endpoint mean change from baseline overall severity at day 7. Secondary endpoints included individual (eye dryness, blurred vision, irritation, light sensitivity, tiredness, burning/stinging, itching, pain); frequency (measured as percentage time experienced) most bothersome symptom, awareness symptoms, fluctuation quality vision; satisfaction. Ninety-nine patients (85.9% female; age range 35–81 years). met: (SD) decreased significantly 72.1 (17.0) to 27.8 (22.3) 7 (mean change, − 44.5; P < 0.0001). Mean experiencing 77.9% 34.7% (P Significant reductions also observed all postbaseline assessments Median ratings 83.0 86.0 90.0 14. Early course PFHO, experienced significant severity. Treatment high. ClinicalTrials.gov identifier NCT06309953.

Язык: Английский

Characterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland: Novel Insights into Diabetic Dry Eye Pathogenesis

American Journal Of Pathology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский